TGTX
High convictionTG Therapeutics, Inc.
Healthcare · NASDAQ
$8.1B mkt cap
Brief updated Jun 21, 2026
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include
TGTX's explosive 641% revenue growth masks a DCF signal that should stop bulls cold.
TG Therapeutics has transformed from a development-stage bet into a commercial-stage biopharmaceutical with reported revenue growth of 641% year over year, driven by the commercial ramp of its MS drug Briumvi. Gross margins of 8,304% and a net margin of 6,595% reflect the economics of a royalty-like drug launch with minimal cost of goods — the numbers look extraordinary because they are, for now. The analyst consensus is firmly bullish and the P/E sits at just 16.6x, which appears cheap against those growth figures. But the DCF intrinsic value is deeply negative at negative 63 dollars, signaling that discounted future cash flows do not support the current price — the tension between the trailing growth story and the forward cash generation picture is the central risk the consensus is glossing over.
Why now
The market is in active risk-off rotation triggered by geopolitical escalation — U.S. strikes on Iran have pushed the Nasdaq and S&P down over 1% with the Dow shedding 600 points, creating an environment where high-multiple growth names get repriced fast even when earnings look clean. TGTX's composite conviction score of 49 out of 100 sits squarely in the middle — not a name institutions are rushing to defend in a flight-to-safety tape.
Key risks
The negative DCF value is the loudest warning: if Briumvi's revenue growth decelerates as the initial launch bolus normalizes, the multiple on current earnings loses its justification quickly. Competitive pressure in the anti-CD20 MS space from established players like Roche and Novartis could compress pricing and limit market share gains before the cash flow profile matures. The current macro environment adds a timing risk — geopolitical shocks historically accelerate rotation out of mid-cap biotech regardless of company-specific fundamentals.
What to watch
Watch Briumvi net revenue in each of the next two quarterly earnings prints — any sequential deceleration below 15% quarter over quarter would signal the launch peak is in and force a rerating. Monitor gross-to-net discount trends and any payer coverage decisions, as formulary positioning changes are the earliest indicator of whether the unit economics hold at scale.
S&P 500, Dow, Nasdaq Futures Decline As US Launches Fresh ‘Self-Defense Strikes’ On Iran: SMCI, TLRY, DKNG, CBRL In Focus
The US has launched fresh 'self-defense strikes' on Iran, leading to a decline in S&P 500, Dow, and Nasdaq futures, as geopolitical tensions escalate and investors become risk-averse. This escalation may lead to further market volatility and potential supply chain disruptions.
Jun 10, 2026
Nasdaq, S&P Drop 1%, Dow Sinks 600 Points as Trump Iran Threat Sparks Market Panic
The US President's threat against Iran has sparked market panic, leading to a significant drop in major stock indexes, including the Nasdaq, S&P, and Dow Jones. This escalation in geopolitical tensions is causing investors to become risk-averse, seeking safer assets.
Jun 10, 2026
Defense Stocks Fall Despite Trump’s Promise of More Iran Strikes
The US has promised more strikes against Iran, escalating tensions in the region, which could lead to increased volatility in global markets. Despite this, defense stocks have fallen, potentially indicating a mismatch between market expectations and geopolitical reality.
Jun 10, 2026
Dow Tumbles Over 900 Points On Iran Strikes: Investor Sentiment Weakens Further, Greed Index Remains In 'Fear' Zone
The Dow Jones index plummeted over 900 points due to Iran's strikes, significantly weakening investor sentiment and pushing the Greed Index into the 'Fear' zone, indicating a heightened sense of risk aversion among investors.
Jun 11, 2026
Earnings surprises
-26.1%
2026-05
-60.0%
2026-02
+912.5%
2025-11
-46.9%
2025-08
-83.3%
2025-05
TSMC stock drops 4.1% amid a $2 trillion AI rout, indicating a potential shift in investor sentiment towards AI-related stocks and the broader tech sector. This event may have implications for the tech industry and the global economy.
The US equity indexes are sliding ahead of Fed Governor Warsh's press briefing and big-tech results, as President Trump vows to hit Iran hard, escalating geopolitical tensions. This escalation could lead to increased market volatility and risk aversion.
The equities market is experiencing intraday losses ahead of the highly anticipated Federal Reserve decision, which could significantly impact market direction and investor sentiment. The decision, coupled with major tech earnings reports, is poised to influence the overall economic outlook.
TSMC's Japan semiconductor fabrication plant is gradually resuming operations following an earthquake-induced disruption. This matters because TSMC is a critical node in the global semiconductor supply chain, and even partial outages can ripple through electronics and chip-dependent industries.
US Strategic Petroleum Reserve levels have fallen to a 43-year low, reducing the government's capacity to buffer oil price shocks at a time of active Middle East conflict. This structural vulnerability in US energy policy raises concerns about energy security and the ability to respond to supply disruptions.
Generated Sun, 21 Jun 2026 06:30:32 GMT by Decifer intelligence engine. For informational purposes only — not investment advice. Decifer Intelligence Hub.